DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA230280
Title:
Toxicology of Perfluorodecanoic Acid
Descriptive Note:
Final rept. 1 Jun 1985-31 May 1990
Corporate Author:
WISCONSIN UNIV-MADISON SCHOOL OF PHARMACY
Report Date:
1990-11-01
Pagination or Media Count:
17.0
Abstract:
Despite hypothyroxinemia, PFDA-treated rats are not functionally hypothyroid. Furthermore, any alteration in functional thyroid status can be dissociated from the overt toxicity i.e., severe hypophagia and body weight loss. PFDA exerts effects on neutral lipid metabolism in both liver and carcass of the rat. At 7 days following a single administration of PFDA, hepatic esterification of free fatty acid into TG and CE was increased yet the expected augmentation in the export of these neutral lipids from liver into plasma was absent. An efficient chemical method was developed for the purification of commercially available PFDA that contains contaminants of mono- and diprotio-substituted materials. PFDA of high specific activity has been synthesized with 14 C-labeling in the C-1 position. In vivo experiments indicate that perfluorinated acid derived radioactivity found in rat tissues behaves similarly to PFDA or PFOA added directly to frozen rat tissue. Hepatic oxidation of long-chain medium-chain and short-chain fatty acids was unaffected by pretreatment with PFDA or PFOA. Similarly, esterification was not affected.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE